Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Neos Therapeutics (NEOS)

Neos Therapeutics (NEOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Neos Therapeutics 2940 NORTH HIGHWAY 360 GRAND PRAIRIE TX 75050 USA

www.neostx.com P: 972-408-1300 F: 972-408-1143

Description:

Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.

Key Statistics

Overview:

Market Capitalization, $K 57,221
Shares Outstanding, K 49,757
Annual Sales, $ 64,650 K
Annual Net Income, $ -16,900 K
Last Quarter Sales, $ 12,540 K
Last Quarter Net Income, $ -4,910 K
60-Month Beta 1.45
% of Insider Shareholders 3.80%
% of Institutional Shareholders 20.83%
Float, K 47,866
% Float 96.20%

Growth:

1-Year Return 53.33%
3-Year Return -87.01%
5-Year Return -88.93%
5-Year Revenue Growth 8,406.58%
5-Year Earnings Growth 98.77%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 03/26/21
Earnings Per Share ttm -0.44
EPS Growth vs. Prev Qtr 9.09%
EPS Growth vs. Prev Year -150.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

NEOS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -28.46%
Profit Margin % -26.14%
Debt/Equity -0.67
Price/Sales 1.00
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.41
Interest Coverage -1.11
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar